Stem cell eye injections for retinitis pigmentosa
Treatments studied
Part of Eyes & vision, Genetic & congenital clinical trials.
This study tests whether a single injection of umbilical cord stem cells around the eye can safely help slow or improve vision loss from retinitis pigmentosa, a genetic eye disease. It also checks how long any benefits might last, using regular eye tests and a quality-of-life survey.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have retinitis pigmentosa and your side vision has narrowed to about 25–50% of normal.
- You must be willing to receive an injection around the eyeball with stem cells taken from human umbilical cord tissue.
- You must be able to attend regular eye tests, including vision checks, side vision maps, OCT scans, and electrical response tests.
- You are not pregnant or nursing, and you do not test positive for HIV.
- You do not have other eye diseases like glaucoma, cataracts, diabetic retinopathy, or uveitis.
- You are not taking immunosuppressive drugs or other medications that could interfere with stem cell growth.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether stem cells from donated umbilical cord tissue can slow down or stop vision loss in people with retinitis pigmentosa, a condition that causes progressive blindness. You would receive these cells as injections around your eye and will be closely monitored with several vision tests.
This trial tests whether tiny particles from stem cells, called extracellular vesicles, can help people with retinitis pigmentosa. It aims to see if these particles are safe and can improve vision.
This study looks at stem-cell treatment to help vision in adults whose retina or optic nerve damage is not expected to improve on its own. You may be a candidate if your eye exam shows documented, stable or slowly changing damage and you can safely complete follow-up eye visits.
This study tests a gene-editing drug, ZVS203e, injected into one eye to see if it is safe and tolerable for people with retinitis pigmentosa caused by a specific genetic change in the RHO gene. It may help slow vision loss or improve vision, but the main goal is to check safety.
This experimental gene therapy (ZM-02) is designed for people with advanced retinitis pigmentosa who have very poor vision (counting fingers or worse). It aims to see if the treatment is safe and can improve vision by replacing a faulty gene in the retina.
This trial tests a new medicine, DSP-3077, given as a single injection into one eye to see if it is safe for people with retinitis pigmentosa. It is for adults with advanced vision loss who have no other major eye diseases.
Hear when a new Retinitis Pigmentosa trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.